Publications

Search our bibliography using the filters on the right-hand side.

Displaying 1 through 50 of 66 publications.

Ronquest N, Zhang Y, Paret K, Armstrong S, Mostovoy L, Berggren R. Identifying the value drivers in obesity treatment: a targeted review of weight loss effects on health economic outcomes. Poster to be given at the ISPOR Europe 2024; November 17, 2024. Barcelona, Spain.

Paret K, Chaiyakunapruk N, Ronquest N, Pearson I. Introduction to best practices for country adaptations of economic models - virtual. Presented at the 2024 Virtual ISPOR Short Course Program; October 2, 2024.

Sawant R, Paret K, Petrillo J, Koenig A, Wolowacz S, Ronquest N, Rickards H. Health state utility estimates for value assessments of novel treatments in Huntington's disease: a systematic literature review. Health Qual Life Outcomes. 2024 Apr 16;22(1):33. doi: 10.1186/s12955-024-02242-1

Drummond MF, Augustovski F, Bhattacharyya D, Campbell J, Chaiyakunapruk N, Chen Y, Galindo-Suarez RM, Guerino J, Mejia A, Mujoomdar M, Ollendorf D, Ronquest N, Torbica A, Tsiao E, Watkins J, Yeung K, ISPOR HTA Council Working Group on HTA in Pluralistic Healthcare Systems collaborators. Corrigendum to Challenges of health technology assessment in pluralistic healthcare systems: an ISPOR Council Report: [Value in Health 25 (2022) 1257-1267/3488]. Value Health. 2023 Dec;26(12):1811. doi: 10.1016/j.jval.2023.06.010

Ronquest N, Paret K, Mladsi DM, Lee LJ. Exploring the value of country-specific cost-effectiveness models in early stages of drug development. Poster presented at the ISPOR Europe 2023; November 2023. Copenhagen, Denmark. [abstract] Value Health. 2023 Dec; 26(12 supplement):S94. doi: 10.1016/j.jval.2023.09.493

Paret K, Ronquest N, Droege M. Economic modeling considerations for rare neurodegenerative diseases of infancy and early childhood. Poster presented at the ISPOR Europe 2022; November 9, 2022. Vienna, Austria. [abstract] Value Health. 2022 Dec 1; 25(12):S171. doi: 10.1016/j.jval.2022.09.830

Ronquest N, Clinkscales M, Paret K. How are United States ICER'S evidence ratings determined?: A systematic review of ICER'S evidence ratings in evidence reports for new drugs in 2020 and 2021. Poster presented at the ISPOR Europe 2022; November 7, 2022. Vienna, Austria. [abstract] Value Health. 2022 Dec 1; 25(12):299-300. doi: 10.1016/j.jval.2022.09.1479

Petrillo J, Paret K, Sawant R, Koenig A, Wolowacz S, Ronquest N, Rickards H. Estimation of health state utilities in Huntington's disease: a targeted review. Poster presented at the HSG 2022 Annual Meeting; November 2022. Tampa, FL. [abstract] J Huntingtons Dis. 2022 Oct 31; 11(s1):S31. Previously presented at the European Huntington's Disease Network (EHDN) 2022 Plenary Meeting. doi: 10.3233/JHD-229005

Petrillo J, Paret K, Sawant R, Koenig A, Wolowacz S, Ronquest N, Rickards H. Estimation of health state utilities in Huntington's disease: a targeted review. Poster presented at the European Huntington's Disease Network (EHDN) 2022 Plenary Meeting; September 18, 2022. Bologna, Italy. [abstract] J Neurol Neurosurg Psychiatry. 2022 Sep 12; 93(suppl 1):A45-6. doi: 10.1136/jnnp-2022-ehdn.118

Drummond MF, Augustovski F, Bhattacharyya D, Campbell J, Chaiyakanapruk N, Chen Y, Galindo-Suarez RM, Guerino J, Mejia A, Mujoomdar M, Ollendorf D, Ronquest N, Torbica A, Tsiao E, Watkins J, Yeung K, ISPOR HTA Council Working Group on HTA in Pluralistic Healthcare Systems collaborators. Challenges of health technology assessment in pluralistic healthcare systems: an ISPOR Council Report. Value Health. 2022 Aug;25(8):1257-67. doi: 10.1016/j.jval.2022.02.006

Ronquest NA, Paret K, Lucas A, Ciepielewska M, Hagan M. Quantifying the value of introducing an oral drug delivery option for edaravone: a review of analyses evaluating the economic impact of oral versus intravenous formulations. Clinicoecon Outcomes Res. 2022 Jul 27;14:499-511. doi: 10.2147/CEOR.S359025

Drummand M, Members of the ISPOR HTA Council Working Group on HTA in Pluralistic Healthcare Systems, Ronquest N. A case of multitasking: conducting and using HTA and HEOR in pluralistic healthcare systems. Value & outcomes spotlight. 2022 Jul;8(4):7-9.

Herring W, Mladsi DM, Ronquest NA. AD valorem: Alzheimer's disease, atopic dermatitis, and challenges for value assessment in chronic conditions. Poster presented at the ISPOR 2022 Conference; May 17, 2022. Washington, DC. [abstract] Value Health. 2022 Jun; 25(6 S1).

Ronquest NA, Paret K, Gould I, Barnett CL, Mladsi (she/her) DM. The evolution of ICER's review process for new medical interventions and a critical review of economic evaluations (2018-2019): how stakeholders can collaborate with ICER to improve the quality of evidence in ICER's reports. J Manag Care Spec Pharm. 2021 Nov;27(11):1601-12. doi: 10.18553/jmcp.2021.27.11.1601

Ronquest N, Paret K, Gould I, Barnett CL, Mladsi D. Effects of stakeholder engagement with Icer on cost-effectiveness of new interventions: lessons learned from a critical review of evaluations from 2018 to 2019. Presented at the Virtual ISPOR 2021 Conference; May 2021.

Ronquest N, La L, Nag A. Characterizing patients with IBD in Japan: epidemiology, symptoms, treatment pathways and humanistic burden. Poster presented at the 2020 Virtual Japan Digestive Disease Week Conference; November 2020.

Ronquest N, La L, Nag A. The economic burden of inflammatory bowel disease in Japan: results from a systematic literature review. Poster presented at the 2020 Virtual Japan Digestive Disease Week Conference; November 2020.

Bhattacharyya D, Chaiyakunapruk N, Chen Y, Ronquest N. Health technology assessment in multi-payer health care systems: challenges and lessons learned in Asia. Presented at the Virtual ISPOR Asia Pacific 2020; September 15, 2020.

Ling W, Nadipelli VR, Aldridge AP, Ronquest NA, Solem CT, Chilcoat H, Albright V, Johnson C, Learned SM, Mehra V, Heidbreder C. Recovery from Opioid Use Disorder (OUD) after monthly long-acting buprenorphine treatment: 12-month longitudinal outcomes from RECOVER, an observational study. J Addict Med. 2020 Sep;14(5):e233-40. doi: 10.1097/ADM.0000000000000647

Igarashi A, Kusel J, Pearson I, Ronquest N. Do innovative technologies require innovative appraisal techniques? - case studies from recent HTAs in the UK, US and Japan. Presented at the ISPOR 2019 European Conference; November 4, 2019. Copenhagen, Denmark.

Ling W, Nadipelli VR, Solem CT, Ronquest NA, Yeh YC, Learned SM, Mehra V, Heidbreder C. Patient-centered outcomes in participants of a buprenorphine monthly depot (BUP-XR) double-blind, placebo-controlled, multicenter, phase 3 study. J Addict Med. 2019 Nov;13(6):442-9. doi: 10.1097/ADM.0000000000000517.

Wheeler A, Ling W, Nadipelli V, Ronquest N, Aldridge A, Solem C, Peiper N, Learned S, Heidbreder C. Recovery from opioid use disorder post-monthly buprenorphine extended release treatment: 12-month longitudinal outcomes. Poster presented at the 2019 AMCP NEXUS; October 29, 2019. National Harbor, MD. [abstract] J Manag Care Spec Pharm. 2019 Oct; 25(10-a):S14. doi: 10.18553/jmcp.2019.25.10-a.s1

Ling W, Nadipelli VR, Ronquest NR, Aldridge A, Solem CT, Peiper N, Learned S, Heidbreder C. How long should pharmacotherapy last for the treatment of opioid use disorder? Results from a 12-month observational study. Poster presented at the 2019 College on Problems of Drug Dependence 81st Annual Scientific Meeting; June 15, 2019. San Antonio, TX.

Ling W, Nadipelli VR, Solem CT, Farabee D, Ronquest NA, Perrochet B, Learned SM, Deshpande CG, Heidbreder C. Measuring recovery in opioid use disorder: clinical utility and psychometric properties of the Treatment Effectiveness Assessment. Subst Abuse Rehabil. 2019 Jun 5;10:13-21. doi: 10.2147/SAR.S198361

Ronquest NA, Gould IG, Barnett CL, Mladsi DM. A systematic review of ICER evaluations from 2008 to 2018: recent trends in evaluation process and lessons learned. Poster presented at the 2019 ISPOR 24th Annual International Meeting; May 21, 2019. New Orleans, LA. [abstract] Value Health. 2019 May; 22(2):S263-4.

Ling W, Nadipelli V, Ronquest N, Aldridge A, Solem C, Learned S, Heidbreder C, Peiper N. Recovery from OUD post monthly buprenorphine-XR treatment: 12-month longitudinal outcomes. Poster presented at the 2019 American Society of Addiction Medicine (ASAM) 50th Annual Conference; April 5, 2019. Orlando, FL.

Ling W, Nadipelli VR, Solem CT, Ronquest NA, Yeh YC, Learned SM, Mehra V, Heidbreder C. Effects of monthly buprenorphine extended-release injections on patient-centered outcomes: a long-term study. J Subst Abuse Treat. 2019 Mar;110:1-8. doi: 10.1016/j.jsat.2019.11.004

Ling W, Nadipelli VR, Ronquest N, Albright VA, Aldridge AP, Learned SM, Mehra V, Heidbreder C. Remission from chronic opioid use-studying environmental and socio-economic factors on recovery (RECOVER): study design and participant characteristics. Contemp Clin Trials. 2019 Jan;76:93-103. doi: 10.1016/j.cct.2018.11.015

Ling W, Nadipelli V, Solem C, Ronquest NA, Yeh YC, Heidbreder C, Learned S, Mehra V. Impact of RBP-6000 (depot buprenorphine) on patient-reported life changes: a long-term study. Presented at the Australasian Professional Society on Alcohol and other Drugs 49th Annual Conference; November 7, 2018. Auckland, Australia. Previously presented at the American Society of Addiction Medicine 49th Annual Conference.

Ronquest NA, Willson TM, Montejano LB, Nadipelli VR, Wollschlaeger BA. Relationship between buprenorphine adherence and relapse, health care utilization and costs in privately and publicly insured patients with opioid use disorder. Subst Abuse Rehabil. 2018 Sep 21;9:59-78. doi: 10.2147/SAR.S150253

Wollschlaeger BA, Ronquest NA, Montejano LB, Wilson TM, Nadipelli VR. Narcotic pain medication and other concomitant medication use before and after buprenorphine maintenance treatment initiation in patients with opioid dependence. Poster presented at the 2016 PAINWeek Conference; September 2016. Las Vegas, NV. [abstract] Postgrad Med. 2018 Aug; 128(Sup2):63-4. doi: 10.1080/00325481.2016.1224633

Ling W, Nadipelli VR, Solem CT, Ronquest NA, Yeh Y, Heidbrede C, Learned SM. Impact of RBP-6000 (depot buprenorphine) on patient-reported outcomes: a long-term study. Poster presented at the American Society of Addiction Medicine 49th Annual Conference; April 13, 2018. San Diego, CA.

Nadipelli VR, Solem CT, Ronquest NA, Yeh Y, Heidbreder C, Learned SM, Mehra V. Impact of RBP-6000 on patient-reported outcomes in patients with opioid use disorder: results of a randomized, placebo-controlled, phase 3 study. Poster presented at the 41st Association of Medical Education and Research in Substance Abuse (AMERSA) Annual National Conference; November 2017. Washington, DC. doi: 10.1080/08897077.2018.1441944

Ramamohan V, Mladsi D, Ronquest N, Kamat S, Boklage S. An economic analysis of tolvaptan compared with fluid restriction among hospitalized patients with hyponatremia. Hospital Practice. 2017 Aug;45(3):111-7. doi: 10.1080/21548331.2017.1324227

Wollschlaeger BA, Willson TM, Montejano LB, Ronquest NA, Nadipelli VR. Characteristics and treatment patterns of US commercially insured and Medicaid patients with opioid dependence or abuse. J Opioid Manag. 2017 Jul;13(4):207-20. doi: 10.5055/jom.2017.0389

Ruetsch C, Tkacz J, Nadipelli VR, Brady BL, Ronquest N, Un H, Volpicelli J. Heterogeneity of nonadherent buprenorphine patients: subgroup characteristics and outcomes. Am J Manag Care. 2017 Jun 1;23(6):e172-9.

Sabar U, Rycroft C, Ronquest NA, Nadipelli VR, Wollschlaeger B, Akehurst R. Analysis of humanistic burden reveals a need for opioid use disorder (OUD) disease-specific HRQoL instruments. Poster presented at the 2017 ISPOR 22nd Annual International Meeting; May 2017. Boston, MA. [abstract] Value Health. 2017 May; 20(5):A300.

Sabar U, Rycroft C, Ronquest NA, Nadipelli VR, Wollschlaeger B, Akehurst R. The economic burden of opioid use disorder (OUD): results of a structured literature review. Poster presented at the 2017 ISPOR 22nd Annual International Meeting; May 2017. Boston, MA. [abstract] Value Health. 2017 May; 20(5):A298.

Elroy PW, Ronquest NA, Barnes A, Nadipelli VR, Akehurst R. Evaluating the effectiveness of treatments of opioid use disorder based on recovery outcomes: how to bridge the disconnect between clinical trial outcomes and recovery outcomes? Poster presented at the 2016 ISPOR 19th Annual European Congress; October 2016. Vienna, Austria. [abstract] Value Health. 2016 Nov; 19(7):A361.

Mladsi D, Ronquest N, Odom D, Miles L, Saag K. Cost-effectiveness of low-dose submicron diclofenac compared with generic diclofenac. Clin Ther. 2016 Nov;38(11):2418-29. doi: 10.1016/j.clinthera.2016.09.013

Cranmer H, Ronquest NA, Barnes A, Nadipelli VR, Akehurst R. To what extent does the published economic analyses of treatments for opioid use disorder capture its chronic, relapsing nature and its impact on society? Poster presented at the 2016 ISPOR 19th Annual European Congress; November 2016. Vienna, Austria. [abstract] Value Health. 2016 Nov; 19(7):A373.

Cranmer H, Ronquest NA, Barnes A, Nadipelli VR, Akehurst R. Health-related quality of life in opioid use disorder measured by utilities: a systematic literature review. Poster presented at the 2016 ISPOR 19th Annual European Congress; November 2016. Vienna, Austria. [abstract] Value Health. 2016 Nov; 19(7):A387.

Tkacz J, Brady B, Nadipelli V, Volpicelli J, Ronquest N, Un H, Ruetsch C. Opioid use disorder population: who is at risk of medication assisted treatment non-adherence? Poster presented at the 2016 AATOD Conference; October 31, 2016. Baltimore, MD.

Wollschlaeger BA, Montejano LB, Wilson TM, Ronquest N, Nadipelli VR. How do patients diagnosed with opioid use disorders compare to the overall US population of individuals with drug use disorder? Poster presented at the 29th Annual U.S. Psychiatric & Mental Health Congress; October 2016. San Antonio, TX.

Wollschlaeger B, Montejano LB, Wilson TM, Ronquest N, Juneau PL, Nadipelli VR. Real-world evidence: buprenorphine adherence predictive of reduced risk of opioid relapse. Poster presented at the 2016 Academy of Managed Care Pharmacy Nexus; October 2016. National Harbor, MD. [abstract] J Manag Care Spec Pharm. 2016 Oct; 22(10-a):S43.

Wollschlaeger B, Montejano L, Willson T, Ronquest N, Juneau P, Nadipelli V. Factors associated with buperhorphine medication assisted treatment adherence in patients diagnosed with opioid use disorder. Poster presented at the 29th Annual U.S. Psychiatric & Mental Health Congress; October 2016. San Antonio, TX.

Boscarino JA, Kirchner HL, Pitcavage JM, Nadipelli VR, Ronquest NA, Fitzpatrick MH, Han JJ. Factors associated with opioid overdose: a 10-year retrospective study of patients in a large integrated health care system. Subst Abuse Rehabil. 2016 Sep 16;7:131-41. doi: 10.2147/SAR.S108302

Boscarino JA, Kirchner HL, Pitcavage JM, Nadipelli VR, Ronquest NA, Fitzpatrick MH. A 10 year retrospective study of opioid overdoses among patients in a large integrated healthcare system. Poster presented at the 2016 International Conference on Opioids Conference; June 2016. Boston, MA.

Montejano LB, Ronquest NA, Willson TM, Wollschlaeger BA, Cole AL, Nadipelli VR. How to measure 'opioid relapse' in real-world claims data. Poster presented at the 2016 ISPOR 21st Annual International Meeting; May 2016. Washington, DC. [abstract] Value Health. 2016 May; 19(3):A72.

Tkacz JMS, Brady B, Nadipelli VR, Volpicelli J, Ronquest NA. The association between buprenorphine medication assisted treatment adherence and healthcare service utilization and costs. Poster presented at the 2016 ISPOR 21st Annual International Meeting; May 2016. Washington, DC. [abstract] Value Health. 2016 May; 19(3):A187.